SCHEMBL1478624

SCHEMBL1478624

COc1cc(Cl)cc(F)c1C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.50
TRPV4 Q9HBA0 1/20 0.40
PRKDC P78527 1/20 0.39
ALDH1A1 P00352 6/20 0.38
TSHR P16473 3/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GAA P10253 1/20 0.37
CYP1A2 P05177 1/20 0.36
LMNA P02545 3/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HTT P42858 2/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
PKM P14618 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PTGS2 P35354 2/20 0.35
CXCL12 P48061 1/20 0.35
PTGS1 P23219 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15348507 0.86 ERN1 (0.58) ERN1TRPV4PRKDCALDH1A1TSHR
SCHEMBL18366 0.81 ERN1 (0.46) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL1251300 0.81 ERN1 (0.53) ERN1TRPV4PRKDCALDH1A1TSHR
SCHEMBL1349783 0.80 ERN1 (0.41) ERN1ALDH1A1TSHRTDP1MEN1
SCHEMBL16675873 0.79 ERN1 (0.51) ERN1TRPV4PRKDCALDH1A1TSHR
SCHEMBL1645590 0.79 ERN1 (0.62) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL24686301 0.78 ERN1 (0.43) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL15348481 0.78 ERN1 (0.66) ERN1TRPV4PRKDCALDH1A1TSHR
SCHEMBL1630491 0.78 ERN1 (0.50) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL16632430 0.78 PRKDC (0.52) ERN1TRPV4PRKDCALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 US disclosed
EP-3651752-B1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-11-20 EP disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US disclosed
US-11603351-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-03-14 US disclosed
EP-3625222-B1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-07-21 EP disclosed
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2021-04-01 US disclosed
US-20200179383-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2020-06-11 US disclosed
EP-3651752-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2020-05-20 EP disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
CN-101277939-A Acyclic ikur inhibitors BRISTOL MYERS SQUIBB CO (US) 2008-10-01 CN disclosed
EP-1922311-A2 ACYCLIC IKUR INHIBITORS Brystol-Myers Squibb Company (US) 2008-05-21 EP disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed
WO-2007030582-A2 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-15 WO disclosed
WO-2007030582-A2 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603351-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ERN1 2993/4885TRPV4 18/4885PRKDC 3348/4885
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 ERN1 2006/4885TRPV4 138/4885PRKDC 4874/4885
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A ERN1 2993/4885TRPV4 18/4885PRKDC 3348/4885
US-20200179383-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 ERN1 2125/4885TRPV4 130/4885PRKDC 4870/4885
US-20070082909-A1 Acyclic Ikur inhibitors KCNH2, KCNJ2, KCNH3 ERN1 362/4885TRPV4 155/4885PRKDC 1382/4885
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A ERN1 2993/4885TRPV4 18/4885PRKDC 3348/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A ERN1 2993/4885TRPV4 18/4885PRKDC 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.